Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer

E-ISSN： 2212-3970|4|2|125-136

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.4, Iss.2, 2009-06, pp. : 125-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RAS: Target for Cancer Therapy

By Saxena Nandita Lahiri Sitanshu Sekhar Hambarde Shashank Tripathi Rajendra Prasad

Cancer Investigation, Vol. 26, Iss. 9, 2008-11 ,pp. : 948-955

Informa Healthcare

Access to resources Recommend Favorite

Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 9, 2015-01 ,pp. : 1127-1133

Bentham Science Publishers

Access to resources Recommend Favorite

Zoledronic acid inhibits the pentose phosphate pathway through attenuating the RasTAp73G6PD axis in bladder cancer cells

Molecular Medicine Reports, Vol. 12, Iss. 3, 2015-01 ,pp. : 4620-4625

Spandidos Publications

Access to resources Recommend Favorite

DNA Repair Pathway Alterations in Bladder Cancer

By Mouw Kent W.

Cancers, Vol. 9, Iss. 4, 2017-03 ,pp. : 28-28

MDPI

Access to resources Recommend Favorite

Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer

International Journal of Oncology, Vol. 47, Iss. 5, 2015-01 ,pp. : 1711-1724

Spandidos Publications

Access to resources Recommend Favorite